Back HIV/AIDS HIV/AIDS Topics HIV Prevention

Tenofovir Alafenamide Subdermal Implant Shows Promise for HIV PrEP in Beagle Study

A sustained-release subdermal implant was able to maintain consistently high levels of tenofovir in cells with no adverse events in an animal study, offering proof-of-concept that an implant may be a good candidate for HIV pre-exposure prophylaxis, or PrEP, according to a study described in the April 20 edition of Antimicrobial Agents and Chemotherapy.

alt

Read more:

Truvada PrEP Causes Only Minimal Bone Loss, Raltegravir Easier on Bones than PIs

Use of tenofovir/emtricitabine (Truvada) for HIV pre-exposure prophylaxis (PrEP) was associated with a small decrease in bone mineral density that stabilized after the first 6 months, according to study findings reported in the April 23 edition of Clinical Infectious Diseases. Related research showed that HIV-positive people starting an antiretroviral regimen containing the integrase inhibitor raltegravir (Isentress) experienced less bone loss than those taking protease inhibitors.

alt

Read more:

Study Suggests Truvada PrEP Should Start 1 Week Before and Continue 4 Weeks After Sex

An intensive pharmacokinetic study of tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) showed that blood and rectal drugs levels corresponding to high PrEP activity for men who have sex with men (MSM) are reached after about 1 week of daily dosing and appear to remain adequate for several days after the last pill, according to a report in the March 1 edition of Clinical Infectious Diseases. It is not known, however, whether this dosing schedule would work as well for women or other groups.

alt

Read more:

May 18 is HIV Vaccine Awareness Day

May 18 is HIV Vaccine Awareness Day, an annual opportunity to call attention to progress in vaccine science and the need for further research on both preventive vaccines that stop new HIV infections and therapeutic vaccines that help the immune system fight existing infection.

alt

Read more:

BHIVA 2015: HIV+ Men on Antiretroviral Treatment Have Undetectable Rectal Viral Load

A small study assessing the infectiousness of HIV-positive gay men taking antiretroviral therapy has found that all study participants had an undetectable viral load in the rectum, according to a presentation at the British HIV Association (BHIVA) conference last week in Brighton. Men who had rectal gonhorrea or chlamydia did not have detectable virus either, suggesting that concerns about sexually transmitted infections raising the risk of HIV transmission may be unfounded when people are taking effective HIV treatment.

alt

Read more: